Posted on December 10th, 2013 by ajmontpetit
Motility and functional gastrointestinal disorders have high prevalence in the community, cause significant morbidity, and represent a major health care burden. Despite major advances in our understanding of the cellular and molecular basis of gastrointestinal neuromuscular functions, many of these diseases still defy mechanistic explanations. The biopsychosocial model underlying the current classification of functional gastrointestinal disorders recognizes and integrates the pathogenetic role of genetic, environmental, and psychosocial factors but has not been associated with specific molecular mechanisms.
Posted on December 3rd, 2013 by Admin
Mark your calendars for October 6-8, 2014 for the 3rd Annual Individualized Medicine Conference! The Conference will once again be hosted in Rochester, MN, and our team is working hard to make next year's Conference better than ever! If you missed any of the Conference this year, you can see all the Conference talks here, and we'll showcase Dr. Eric Green's kickoff talk below!
Posted on November 27th, 2013 by Admin
Not only is this year celebrating Thanksgiving and the first day of Hanukkah on the same day (aptly titled Thanksgivukkah), tomorrow is also the Surgeon General's National Family History Day. While Genomics and Personalized Medicine play an important role in the diagnosis of many diseases named and unnamed, your family health history brings more information to your provider for better diagnosis and risk management planning.
The Surgeon General created a free website to assist anyone to create a portrait of their family's health. The questionnaire takes roughly 20 minutes to complete, and protects your [...]
Posted on November 26th, 2013 by Admin
Recent research has illustrated that the intestinal microbiome plays a major role in the development of Type 1 diabetes. Researchers at Mayo Clinic, funded by the Iacocca Foundation and a National Institutes of Health RO1 grant, demonstrated that gluten in the diet may in fact modify the intestinal microbiome, increasing incidences of Type 1 diabetes. The findings were published Nov. 13, in PLOS ONE.
The researchers demonstrated that mice fed a gluten-free diet had a dramatically reduced incidence of Type 1 diabetes. These mice were non-obese diabetic mice, and the gluten-free diet protected the mice against Type 1 diabetes. When the researchers added gluten back into the mice diets, it reversed the protective effect the gluten free diet had provided, and there also was a measurable impact of the gluten on the bacterial flora of the mice that might be one way in which gluten could affect the risk for diabetes.
Posted on November 21st, 2013 by Center for Individualized Medicine
A recent publication, featuring the Director of the Biomarker Discovery Program at the Center for Individualized Medicine at Mayo Clinic, George Vasmatzis, examining the role of ASCL1 in the neuroendocrine differentiation of lung adenocarcinoma.
The clinical significance of neuroendocrine differentiation in lung adenocarcinoma, and the most appropriate biomarkers for this assessment, has long been debated. In the absence of a gold standard, investigators have most commonly used immunohistochemical staining of one or a combination of neuroendocrine markers, such as chromogranin, synaptophysin, neuron-specific enolase or neural cell adhesion molecule (CD56/NCAM) to assess the role of neuroendocrine differentiation in lung cancer survival. Notably, previous reports have not included ASCL1, despite the pivotal role this gene has in the development of neuroendocrine cells in the lung.
Posted on November 14th, 2013 by ajmontpetit
Which antiplatelet medication is best after a coronary stent? The costly and potential life-or-death question lingers after most of the 600,000 angioplasties performed every year in the United States. The answer may lie in your genes, but professional cardiovascular societies and many working cardiologists question the U.S. Food and Drug Administration's recent recommendation that patients undergo genetic testing before taking Plavix (clopidogrel bisulfate).
The Tailored Antiplatelet Therapy to Lessen Outcomes after Percutaneous Coronary Intervention (TAILOR-PCI) Study, launched this summer by the Center for Individualized Medicine and the Division of Cardiovascular Diseases at Mayo Clinic, examines whether prescribing heart medication based on a patient's CYP2C19 genotype will help prevent heart attack, stroke, unstable angina, [...]
Posted on November 12th, 2013 by ajmontpetit
Mayo Clinic researchers have shown that a molecule called Cul4 helps to deposit DNA-packaging histone proteins onto DNA, an integral step in cramming yards of genetic code into compact coils that can fit into each cell. When DNA isn’t packaged correctly, it can lead to the genomic instability characteristic of many forms of cancer.
The research is published in the Nov. 7 issue of the journal Cell. The results explain on a molecular level how Cul4 enables the handoff of histones from the proteins escorting them from their birthplace in the cell to their workplace on the DNA, where they can begin wrapping DNA up into tidy units called nucleosomes.
“We suggest that cancer cells may have evolved a mechanism to disrupt proper nucleosome assembly by altering Cul4 and other factors, which in turn could affect the stability of the genome and promote the formation of tumors,” says senior study author Zhiguo Zhang, Ph.D., a molecular biologist at Mayo Clinic.
Posted on November 7th, 2013 by ajmontpetit
Researchers at Mayo Clinic, and the Center for Individualized Medicine, have recently been utilizing genomic sequencing to help develop personalized care treatments for men with castration-resistant prostate cancer, a progressive and incurable stage of prostate cancer that no longer responds to hormone therapies that stop or slow testosterone production.
“Men with castration-resistant prostate cancer have abysmal survival rates, typically living an average of two years once hormone therapies fail,” says Manish Kohli, M.D., a Mayo Clinic oncologist and principal investigator of the Prostate Cancer Medically Optimized Genome-Enhanced Therapy (PROMOTE) study.
The FDA has recently approved several new therapies for use in treating castration-resistant prostate cancer. Many questions remain, however, over which medications to use in individual cases. Researchers and doctors utilize exome sequencing and RNA profiling in the PROMOTE study, to identify biomarkers within prostate cancers that can help identify the optimal drug for each individual patient.